Based in Bloomington, Minnesota, Emerging Therapy Solutions (ETS) is a predictive intelligence platform designed for the payer community to simplify the management of emerging therapy processes. In late May, the company secured $1 million in equity funding from San Francisco, California-based Telegraph Hill Partners, a private equity firm that regularly invests in life science, medical device, and healthcare companies.
Founded in 2018 by healthcare industry veteran and seasoned CEO, David J. McLean, Ph.D., ETS aims to streamline the supply chain specifically for gene and cell therapy systems. Dr. McLean brings 40 years of outstanding experience leading managed care companies, including Medication Management Systems, Inc., that was acquired by Genoa HealthCare in 2017 and NovoLogix, a medical pharmacy management company, that was acquired by CVS in 2013. He has also previously had an executive impact at other companies, one of which managed electronic prescriptions, another organ and tissue transplants, and at a health services company that provided contracting, reinsurance subsidiary, and PBM support.
Healthcare costs in the US are expected to escalate at a much higher rate than other sectors of the economy. Strategies to reduce costs now involve optimizing management of the healthcare supply chain. The transformation of this flow could not only improve the bottom line thus increasing affordability of care, but also enhance the quality of care and expand accessibility.
As indicated on their website, ETS will “drive down cost for payers to increase the rate of innovation for life-saving treatments”. Their model is directed at removing barriers in management, reimbursement and financing, thus introducing greater consistency, continuity and efficiency to the complex relationships that exist in the course of emerging therapies.
The company offers a complete package of outsourced services and analytical software tools for insurance providers and other payers to fully manage costly cell and gene therapy processes that according to the company include “clinical trial pipeline curation, exposure analytics, medical policy and care guidelines developed and recommended by expert physicians, patient placement and tracking, credentialed centers, educational forums, as well as contract and claim solutions.”
BECOME A SPONSOR
Join us in championing the narrative of success, resilience, and ingenuity that defines Nebraska’s startup community. Learn more »
Optimized management of the entire supply chain for these complex new treatments is the solution ETS offers its clients.
Visit www.emergingtherapies.com for more information about this company.
